GNAS Gene (GNAS Complex Locus): Structure, Function, and Clinical Significance
A comprehensive biomedical overview of the GNAS gene, its isoforms, associated diseases, expression patterns, and mutational landscape.
Gene Information Card
| Symbol | GNAS |
|---|---|
| Full Name | GNAS complex locus |
| Gene Type | protein coding |
| Chromosomal Location | 20q13.32 |
| NCBI Gene ID | 2778 ncbi.nlm.nih.gov/gene/2778 |
| Ensembl ID | ENSG00000087460 |
| UniProt ID | Q5JWF2 (GNAS1 isoform); P63092 (Gs alpha) – note: multiple isoforms |
| OMIM ID | 139320 |
| HGNC ID | 4392 |
| Aliases | GNAS1, GPSA, GNAS complex locus, POH, MGC33735, AHO |
Description
The GNAS complex locus on chromosome 20q13.32 is a highly imprinted gene that produces multiple transcripts through alternative splicing and the use of alternative promoters. The most well-known product is the alpha subunit of the stimulatory G protein (Gsα), which couples G protein-coupled receptors to adenylyl cyclase, generating cAMP. The locus also produces other transcripts, including XLαs, ALEX, and neuroendocrine secretory protein (NESP55), each with distinct promoters and imprinting patterns. Mutations in GNAS lead to various human diseases, including McCune-Albright syndrome, fibrous dysplasia, pseudohypoparathyroidism types 1A and 1B, and certain endocrine tumors.
Disease Associations
| Disease category | Pathophysiological mechanism | Genomic evidence |
|---|---|---|
| McCune-Albright Syndrome | Somatic activating mutations (e.g., R201C/R201H) in GNAS lead to constitutive cAMP production, causing fibrous dysplasia, café-au-lait spots, and precocious puberty. | OMIM #174800; ClinVar; COSMIC |
| Fibrous Dysplasia (Polyostotic) | Same activating mutations as McCune-Albright, leading to abnormal osteoblast differentiation and fibrous bone tissue. | OMIM #174800; COSMIC |
| Pseudohypoparathyroidism Type 1A (PHP1A) | Inactivating mutations on the maternal allele reduce Gsα expression, causing resistance to PTH and other hormones, with Albright hereditary osteodystrophy features. | OMIM #103580; ClinVar |
| Pseudohypoparathyroidism Type 1B (PHP1B) | Methylation defects or deletions in the GNAS locus cause loss of maternal allele expression, leading to PTH resistance without AHO. | OMIM #603233; ClinVar |
| Progressive Osseous Heteroplasia (POH) | Inactivating mutations on the paternal allele cause severe heterotopic ossification. | OMIM #166350; ClinVar |
| Pituitary Adenomas (GH-secreting) | Somatic activating mutations (e.g., R201C) in GNAS are found in ~30-40% of somatotroph adenomas, leading to excess GH and acromegaly. | COSMIC; OMIM #102200 |
| Thyroid Adenomas and Carcinomas | Activating GNAS mutations are found in some thyroid tumors, leading to constitutive cAMP signaling and cell proliferation. | COSMIC; ClinVar |
| Ovarian and Testicular Tumors | Activating GNAS mutations have been reported in some sex cord-stromal tumors. | COSMIC |
Expression Profile
Tissue Expression
| Tissue | nTPM | level |
|---|---|---|
| Thyroid | High (nTPM ~ 200) | High expression in thyroid gland, consistent with Gsα role in TSH signaling. |
| Pituitary | High (nTPM ~ 150) | High expression in anterior pituitary, relevant to GH and other hormone regulation. |
| Adrenal Gland | Moderate (nTPM ~ 100) | Expression in adrenal cortex, involved in ACTH signaling. |
| Kidney | Moderate (nTPM ~ 80) | Expression in renal proximal tubules, relevant to PTH action. |
| Bone (Osteoblasts) | Moderate (nTPM ~ 70) | Expression in osteoblasts, critical for bone formation. |
| Brain | Low to moderate (nTPM ~ 50) | Widespread expression in brain, with imprinted isoforms. |
| Liver | Low (nTPM ~ 30) | Low expression, but present. |
| Heart | Low (nTPM ~ 20) | Low expression. |
Cell Line Expression
| Cell Line | nTPM | Notes |
|---|---|---|
| HEK 293 | High (nTPM ~ 150) | Embryonic kidney cells, commonly used for GNAS functional studies. |
| HeLa | Moderate (nTPM ~ 80) | Cervical cancer cell line, expresses GNAS. |
| MCF7 | Moderate (nTPM ~ 70) | Breast cancer cell line, GNAS expression detected. |
| A549 | Low (nTPM ~ 30) | Lung carcinoma cell line, low expression. |
| HepG2 | Low (nTPM ~ 20) | Hepatocellular carcinoma cell line, low expression. |
Data source：Human Protein Atlas（proteinatlas.org）
Mutations & Variants
Hotspot Mutations
| Variant | Type | Frequency | Functional Description |
|---|---|---|---|
| R201C | Missense (activating) | Somatic; common in McCune-Albright and pituitary adenomas | Constitutive activation of Gsα, increased cAMP. |
| R201H | Missense (activating) | Somatic; common in McCune-Albright and pituitary adenomas | Constitutive activation of Gsα, increased cAMP. |
| R201G | Missense (activating) | Somatic; rare | Constitutive activation. |
| Q227L | Missense (activating) | Somatic; rare in tumors | Constitutive activation. |
| Frameshift deletions | Loss-of-function | Germline; cause PHP1A | Reduced Gsα expression or function. |
| Nonsense mutations | Loss-of-function | Germline; cause PHP1A | Truncated protein, loss of function. |
| Splice-site mutations | Loss-of-function | Germline; cause PHP1A | Aberrant splicing, reduced Gsα. |
| Methylation defects | Epigenetic | Germline; cause PHP1B | Loss of maternal allele expression. |
Mutation functional classification
Loss of Function (LOF)
Loss-of-function mutations in GNAS typically involve frameshift, nonsense, or splice-site changes that reduce Gsα protein levels or activity. These are often germline and cause pseudohypoparathyroidism type 1A (when maternal allele affected) or progressive osseous heteroplasia (when paternal allele affected). The mechanism involves haploinsufficiency or dominant-negative effects, leading to impaired cAMP signaling in response to hormones like PTH.
Gain of Function (GOF)
Gain-of-function mutations are typically missense mutations at codons R201 or Q227, which impair GTPase activity, locking Gsα in the active GTP-bound state. This leads to constitutive adenylyl cyclase activation and elevated cAMP, driving uncontrolled cell proliferation and hormone secretion. These are somatic and cause McCune-Albright syndrome, fibrous dysplasia, and various endocrine tumors.
Dominant Negative (DN)
Some GNAS mutations may act in a dominant-negative manner, particularly those that produce truncated proteins that interfere with the normal Gsα function. However, the classic dominant-negative mechanism is not well-established for GNAS; most loss-of-function mutations are haploinsufficient. In rare cases, certain missense mutations may exert a dominant-negative effect by disrupting G protein coupling.
View complete mutation data：
Gene Ontology (GO)
| • G protein-coupled receptor signaling pathway | • Adenylate cyclase activating G protein-coupled receptor signaling pathway |
| • GTPase activity | • Signal transducer activity |
| • Hormone-mediated signaling pathway | • cAMP biosynthetic process |
| • Cellular response to hormone stimulus | • Positive regulation of cAMP-mediated signaling |
| • Ossification | • Bone development |
Pathways
• Gs alpha signaling pathway
• cAMP signaling pathway
• GPCR downstream signaling
• PKA signaling
• Hormone signaling (PTH
• TSH
• ACTH
• LH
• FSH)
• cAMP metabolic process
Protein Summary
The GNAS gene encodes the alpha subunit of the stimulatory G protein (Gsα), a critical component of GPCR signaling. Gsα binds GTP and activates adenylyl cyclase, producing cAMP, which activates protein kinase A (PKA) and downstream effectors. The protein is ubiquitously expressed but particularly important in endocrine tissues. Alternative splicing and imprinting generate multiple isoforms with distinct functions. Mutations that constitutively activate Gsα lead to tumorigenesis and developmental disorders, while inactivating mutations cause hormone resistance syndromes.
Related Services
Related Products
| Product name | Cat.No. | Species | Gene ID | |
|---|---|---|---|---|
| GNAS Knockout HEK293 Cell Line | EDJ-KQ725 | Human | 2778 | Details Get a Quote |
| GNAS Knockout HeLa Cell Line | EDJ-KQ18093 | Human | 2778 | Details Get a Quote |
| GNAS Knockout A-549 Cell Line | EDJ-KQ20696 | Human | 2778 | Details Get a Quote |
| GNAS Knockout HCT 116 Cell Line | EDJ-KQ20698 | Human | 2778 | Details Get a Quote |
| GNAS (p.E104K) Point Mutation in HAP1 Cell Line | EDC03505 | Human | 2778 | Details Get a Quote |
| GNAS (p.A478V) Point Mutation in HAP1 Cell Line | EDC03506 | Human | 2778 | Details Get a Quote |
| GNAS (p.I828=) Point Mutation in HAP1 Cell Line | EDC03507 | Human | 2778 | Details Get a Quote |
Displaying Records 1 To 7 Of 7 Records
